CSTONE PHARMA-B (02616) has entered into a clinical development collaboration with Kimia Therapeutics to jointly advance an innovative drug candidate targeting a key repair pathway in solid tumors.

CSTONE PHARMA-B (02616) announced that the company has entered into a collaboration with Kimia Therapeutics, Inc. ("Kimia"), a biopharmaceutical company focused on the research and development of innovative oncology and immunology drugs. The two parties will jointly advance the clinical development of a solid tumor drug candidate with first-in-class potential that targets a key DNA damage response (DDR) pathway critical to solid tumor survival. CStone Pharma will lead the clinical development of the candidate drug in mainland China and Australia. This collaboration further confirms international recognition of CStone Pharma's mature clinical development and drug registration capabilities, and aligns with the company's strategy of prudently advancing external innovation and global expansion. At the same time, CStone Pharma will share in the global commercial value of this first-in-class drug through milestone payments and sales royalties. Kimia is headquartered in Berkeley, California, and leverages its self-developed integrated ATLAS platform to enable AI-powered drug discovery and develop small-molecule drugs. Kimia is a portfolio company of the well-known life sciences investment firm The Column Group (TCG). TCG focuses on incubating and investing in biotechnology companies across the full development cycle, from early-stage scientific innovation and clinical development to strategic transactions.